Haemonetics (NYSE: HAE) furnishes Q3 and nine-month results press release

Rhea-AI Filing Summary

Haemonetics Corporation filed a current report stating that it issued a press release with financial results for the third quarter and nine months ended December 27, 2025. The press release, dated February 5, 2026, is furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act.

0000313143false00003131432026-02-052026-02-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 5, 2026

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

001-14041

04-2882273

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

125 Summer Street

Boston, MA 02110

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $.01 par value per share			HAE			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition. 

On February 5, 2026, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The foregoing information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits.

Exhibit Number						Description
99.1						Press Release of Haemonetics Corporation dated February 5, 2026 announcing financial results for the third quarter and nine months ended December 27, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

Date: February 5, 2026

By:

/s/ Christopher A. Simon

Name:

Christopher A. Simon

Title:

President and Chief Executive Officer

FAQ

What did Haemonetics Corporation (HAE) disclose in its latest 8-K filing?

Haemonetics Corporation disclosed that it issued a press release announcing financial results for the third quarter and nine months ended December 27, 2025. This press release is included as Exhibit 99.1 and is furnished, rather than filed, under the Securities Exchange Act of 1934.

Which period do Haemonetics Corporation’s newly announced financial results cover?

The financial results announced by Haemonetics Corporation cover its third quarter and the nine-month period ended December 27, 2025. These results are described in a press release dated February 5, 2026, which is attached to the current report as Exhibit 99.1.

How is the Haemonetics Corporation press release treated under the Exchange Act?

The Haemonetics Corporation press release included as Exhibit 99.1 is expressly stated as being furnished, not filed, for purposes of Section 18 of the Exchange Act. This means it is not subject to Section 18 liabilities and is not automatically incorporated by reference into other filings.

What exhibits are included with Haemonetics Corporation’s February 5, 2026 Form 8-K?

The Form 8-K includes Exhibit 99.1, which is a press release dated February 5, 2026 announcing financial results for the third quarter and nine months ended December 27, 2025. It also includes Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Who signed Haemonetics Corporation’s February 5, 2026 8-K report?

The February 5, 2026 Form 8-K for Haemonetics Corporation was signed on behalf of the company by Christopher A. Simon, who is identified in the report as the President and Chief Executive Officer. His electronic signature appears on the signature page of the filing.

On what date did Haemonetics Corporation issue the press release about its financial results?

Haemonetics Corporation issued the press release announcing its financial results on February 5, 2026. This press release, dated the same day, is attached as Exhibit 99.1 to the current report and covers the third quarter and nine months ended December 27, 2025.